An overview of topical lipid-based and polymer-based nanocarriers for treatment of psoriasis

Psoriasis is a consistently recurring, inflammatory skin disease, affecting about 2-5 % of the world population. Different types of psoriasis can be observed such as guttate psoriasis, pustular psoriasis, psoriatic arthritis, scalp psoriasis, flexural psoriasis etc. Several therapeutic approaches are available for the treatment of psoriasis. However, none of them are entirely safe and effective to treat the disease without compromising patient compliance. The traditional treatment plan is associated with harmful side effects such as immune system sup-pression and damage of essential organs at high doses, which poses a challenge to treat psoriasis. Novel drug delivery systems are being developed to replace traditional therapy in order to address these shortcomings. Currently, nanoformulations have gained widespread application for treatment of psoriasis. Researchers have developed different types of lipid-based nanoparticles like liposomes, niosomes, ethosomes, transethosomes, nanostructured lipid carriers and solid lipid nanoparticles. These innovative formulations provide advantages in terms of reduction in dose, dosing frequency, dose-dependency with enhanced efficacy, improved encapsulation efficiency, controlled release, increased surface area, high bioavailability and greater stratum corneum perme-ability. This review highlights detailed and comparative discussion of lipid-based and polymer-based nano-particles for psoriasis along with the pathophysiology and other treatments of psoriasis.

Automated summary

Psoriasis is a recurrent, inflammatory skin disease, affecting 2-5% of the global population. Traditional treatments have limitations and can cause harmful side effects. Novel drug delivery systems, such as lipid-based nanoparticles, are being developed to provide safer and more effective treatment options.